Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1
Public ClinicalTrials.gov record NCT06071767. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I/IIa Randomized, Placebo-Controlled Trial of Conserved-Mosaic T-cell Vaccine in a Regimen With Vesatolimod and Broadly Neutralizing Antibodies in Adults Initiated on Suppressive Antiretroviral Therapy During Acute HIV-1
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the safety, tolerability, and efficacy of therapeutic vaccination with chimpanzee adenovirus ChAdOx1- and poxvirus modified vaccinia Ankara (MVA)-vectored conserved mosaic T-cell vaccines in a sequential regimen with the toll-like receptor 7 (TLR7) agonist vesatolimod (VES) and two broadly neutralizing antibodies (bNAbs) compared to placebo, to induce HIV-1 control during analytic treatment interruption (ATI).
Study identification
- NCT ID
- NCT06071767
- Recruitment status
- Suspended
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 36 participants
Conditions and interventions
Conditions
Interventions
- ChAdOx1.tHIVconsv1 Biological
- ChAdOx1.HIVconsv62 Biological
- MVA.tHIVconsv3 Biological
- MVA.tHIVconsv4 Biological
- Vesatolimod (VES) Drug
- GS-5423 Drug
- GS-2872 Drug
- Placebo Biological
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 1, 2024 (Actual)
- Primary completion
- Apr 29, 2028 (Estimated)
- Completion
- Aug 1, 2029 (Estimated)
- Last update posted
- Sep 2, 2026
2024 – 2029
United States locations
- U.S. sites
- 9
- U.S. states
- 9
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California, San Diego AntiViral Research Center CRS | San Diego | California | 92103 | — |
| Ponce de Leon Center CRS | Atlanta | Georgia | 30308 | — |
| Northwestern University CRS | Chicago | Illinois | 60611 | — |
| Massachusetts General Hospital CRS (MGH CRS) | Boston | Massachusetts | 02114 | — |
| Washington University Therapeutics CRS | St Louis | Missouri | 63110 | — |
| Chapel Hill CRS | Chapel Hill | North Carolina | 27599 | — |
| Ohio State University CRS | Columbus | Ohio | 43210 | — |
| Penn Therapeutics CRS | Philadelphia | Pennsylvania | 19104 | — |
| Houston AIDS Research Team CRS | Houston | Texas | 77004 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06071767, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 2, 2026 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06071767 live on ClinicalTrials.gov.